Your Health, We Care
Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
from FDA，2024.01
Koselugo is a class of precision small molecule MEK inhibitors (also regarded as schizogenic activation antagonists), and its core efficacy focuses on targeted therapy for specific···【more】
Article source：Lucius LaosRelease date：2024-08-22Recommended：123
Koselugo is a small molecule MEK inhibitor (figogen activation inhibitor) that is mainly used for the treatment of certain types of tumors, especially in the treatment of neurofibr···【more】
Article source：Lucius LaosRelease date：2024-08-22Recommended：115
Koselugois a small molecule drug inhibitor targeting the MEK signaling pathway, and its core utility is focused on specific neurofibromas and has demonstrated excellent therapeutic···【more】
Article source：Lucius LaosRelease date：2024-08-21Recommended：116
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
